THERMOGENESIS CLOSES $2.05 MILLION PUBLIC OFFERING
Summary
Wainwright & Co. acted as exclusive placement agent for the offering.The securities were offered and sold pursuant to a registration statement on Form S-1, as amended (File No. 333-264242), previously filed with the Securities and Exchange Commission ("SEC") and declared effective on October 25, 2022. Electronic copies of the final prospectus relating to the offering may be obtained for free by visiting the SECs website at www.sec.gov or from H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, by email at [email protected] or by telephone at (212) 856-5711.This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. When used in this press release, the words "anticipate," "believe," "estimate," "expect" and similar expressions as they relate to the Company, or its management are intended to identify such forward-looking statements.